NDA 018737 · Journey
Exelderm
Sulconazole Nitrate · Topical
Last checked: Nov 20, 2026Latest source record: Nov 26, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Feb 28, 1989
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
23
13 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 23, 2024.
INDICATIONS AND USAGE SULCONAZOLE NITRATE cream 1.0% is an antifungal agent indicated for the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagro- phytes, Epidermophyton floccosum , and Microsporum canis ,* and for the treatment of tinea versicolor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 28, 1989 Original approval · Type 3 - New Dosage Form
1 products under this application
- EXELDERM · SULCONAZOLE NITRATE 1% · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sulconazole Nitrate" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective3
- anxiety2
- erythema2
- fatigue2
- generalised pustular psoriasis2
- herpes zoster2
- hypotension2
- nausea2
- pruritus2
- abnormal dreams1
- acute kidney injury1
- altered state of consciousness1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Exelderm (Sulconazole Nitrate)
2024 spending
$80K
Beneficiaries
103
142 claims
Per beneficiary
$775
$13.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $49,018 |
| 2023 | $111,253 |
| 2024 | $79,794 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Athlete's foot.
Crawford F · BMJ Clin Evid 2009 · Systematic Review
- 1% sulconazole cream v 2% miconazole cream in the treatment of tinea versicolor. A double-blind, multicenter study.
Tanenbaum L, Anderson C, Rosenberg MJ, et al. · Arch Dermatol 1984 · Clinical Trial, Comparative Study
- Sulconazole nitrate 1.0 percent cream: a comparison with miconazole in the treatment of tinea pedis and tinea cruris/corporis.
Tanenbaum L, Anderson C, Rosenberg MJ, et al. · Cutis 1982 · Clinical Trial, Comparative Study
- Treatment of pityriasis versicolor: comparison of sulconazole nitrate 1% solution and clotrimazole 1 % solution.
Tham SN · Australas J Dermatol 1987 · Clinical Trial, Comparative Study
- Treatment of cutaneous candidiasis: a double blind, parallel comparison of sulconazole nitrate 1% cream and clotrimazole 1% cream.
Rajan VS, Thirumoorthy T · Australas J Dermatol 1983 · Clinical Trial, Comparative Study
- Sulconazole nitrate cream 1 percent for treating tinea cruris and corporis.
Tanenbaum L, Taplin D, Lavelle C, et al. · Cutis 1989 · Clinical Trial, Comparative Study
Sponsor: Journey
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.